Ignite Creation Date:
2025-12-24 @ 1:37 PM
Ignite Modification Date:
2026-01-01 @ 11:23 AM
Study NCT ID:
NCT01349595
Status:
TERMINATED
Last Update Posted:
2015-10-28
First Post:
2011-05-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
Sponsor:
Mark Stegall
Organization:
Study Overview
Official Title:
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
Status:
TERMINATED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study halted due to lack of funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if treating patients who have high levels of donor specific alloantibodies post-transplant with bortezomib might prevent the development of transplant glomerulopathy and preserve allograft function.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: